ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen

Adrenocortical carcinoma (ACC) is a rare but aggressive disease that lacks definitive treatment. We aim to evaluate role of ASXL1 in ACC and exploit its therapeutic merits therein. We performed in silico reproduction of datasets of the Cancer Genome Atlas (TCGA), GDSC (Genomics of Drug Sensitivity i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liang, Lyu, Yinfeng, Li, Yuqing, Li, Kunping, Wen, Hui, Feng, Chenchen, Li, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507286/
https://www.ncbi.nlm.nih.gov/pubmed/34536950
http://dx.doi.org/10.18632/aging.203534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507286/
https://www.ncbi.nlm.nih.gov/pubmed/34536950
http://dx.doi.org/10.18632/aging.203534

Ejemplares similares